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Cardiovascular disease is a leading cause of death with increasing economic burden. The 
pathogenesis of cardiovascular diseases is complex, but can arise from genetic and/or 
environmental risk factors. This can lead to dysregulated gene expression in numerous 
cell types including cardiomyocytes, endothelial cells, vascular smooth muscle cells, 
and inflammatory cells. While initial studies addressed transcriptional control of gene 
expression, epigenetics has been increasingly appreciated to also play an important 
role in this process through alterations in chromatin structure and gene accessibility. 
Chromatin-modifying proteins including enzymes that modulate DNA methylation, his-
tone methylation, and histone acetylation can influence gene expression in numerous 
ways. These chromatin modifiers and their marks can promote or prevent transcription 
factor recruitment to regulatory regions of genes through modifications to DNA, histones, 
or the transcription factors themselves. This review will focus on the emerging question 
of how epigenetic modifiers and transcription factors interact to coordinately regulate 
gene expression in cardiovascular disease. While most studies have addressed the roles 
of either epigenetic or transcriptional control, our understanding of the integration of 
these processes is only just beginning. Interrogating these interactions is challenging, 
and improved technical approaches will be needed to fully dissect the temporal and 
spatial relationships between transcription factors, chromatin modifiers, and gene 
expression in cardiovascular disease. We summarize the current state of the field and 
provide perspectives on limitations and future directions. Through studies of epigenetic 
and transcriptional interactions, we can advance our understanding of the basic mecha-
nisms of cardiovascular disease pathogenesis to develop novel therapeutics.
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iNTRODUCTiON
Cardiovascular disease is the leading cause of death in the United States and worldwide (1). More 
than one in three adults in the United States has one or more types of cardiovascular diseases, which 
include coronary heart disease, high blood pressure, congenital heart defects, and heart failure, 
among others (1). In addition to health burdens, cardiovascular disease generates economic burdens 
greater than $316 billion dollars per year in the United States and projected to reach $918 billion by 
Table 1 | list of chromatin modifiers discussed in this review and their respective roles.
Chromatin modifier Function activity Role
p300 Histone acetyltransferase (HAT) Acetylation of histones, non-histone proteins Activating
CBP HAT Acetylation of histones, non-histone proteins Activating
HDAC1–9, 11 Histone deacetylase (HDAC) Deacetylation of histones, non-histone proteins Repressivea
SIRT HDAC Deacetylation of histone, non-histone proteins Repressivea
UTX (KDM6A) Histone demethylase Demethylation of H3K27 Activating
JMJD2a (KDM4A) Histone demethylase Demethylation of H3K9, H3K36 Activating
KDM3A (JMJD1A) Histone demethylase Demethylation of H3K9 Activation
JMJD6 Histone demethylase Demethylation of H3R Repressive
Protein arginine methyltransferase 4 Histone methylation Methylation of H3R17 Activation
EZH2 Histone methyltransferase Methylation of H3K27 Repressive
COMPASS (including ASH2, WDR5) SET/MLL family of methyltransferases H3K4 methylation Activating
DNMT DNA methylation Methylation of DNA cytosines Repressive
Ten–eleven translocation DNA hydroxymethylation Hydroxymethylation of DNA methylcytosines Activation
This is only a subset of the known chromatin modifying proteins and their activity. Whether there is a role for other chromatin modifying proteins in regulation of gene expression in 
cardiovascular disease through interaction with transcription factors is unknown.
aReported activating role although primarily considered repressive.
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2030 and over one trillion dollars worldwide (1). Numerous risk 
factors, both heritable and behavioral, contribute to cardiovas-
cular disease. These include genetics, high blood pressure, high 
cholesterol, diabetes, smoking, obesity, physical inactivity, and 
others (1).
The multiple cell types that make up the heart and vasculature 
can contribute to cardiovascular disease in different ways. The 
heart is made up of cardiac myocytes and fibroblasts and is sup-
plied by an extensive network of blood vessels, which in turn are 
composed of multiple cell types including fibroblasts and connec-
tive tissue, smooth muscle cells that regulate vessel tone, and the 
endothelial cells (ECs) that line the vessel and are in direct contact 
with the blood and its cellular components. Cardiovascular dis-
eases can arise from numerous factors including structural heart 
and vascular defects, inflammatory responses, and endothelial 
and vascular smooth muscle dysfunction. Dysfunction at the tis-
sue level can arise from different types of molecular pathologies 
such as genetic mutations and impaired signaling mechanisms. 
These changes are ultimately manifest at the level of gene expres-
sion. Traditionally, investigation into underlying mechanisms has 
been mediated at the level of transcription of genes into mRNA 
and, ultimately, to protein. More recently, it has been appreciated 
that epigenetics provides a major influence on gene expression 
and cell function.
Epigenetics is defined as a stably heritable phenotype resulting 
from changes in a chromosome without alterations in the DNA 
sequence (2). While non-coding RNAs are also epigenetic media-
tors, this review will focus on enzymatic epigenetic regulators. 
Each chromosome is made up of DNA and associated proteins. 
The complex of DNA wrapped around octamers of histone 
proteins is known as chromatin, which functions to package and 
compact DNA into each nucleus. The structural and functional 
subunit of chromatin is the nucleosome, which is composed of 
eight histone proteins (two of each of the histones H2A, H2B, 
H3, and H4) that form an octamer that binds approximately 146 
base pairs of DNA (3). Covalent modifications can be made to 
histone tails or the DNA itself. These include DNA modifications 
such as cytosine methylation [5-methylcytosine (5mC)] or post-
translational modification of histone tails including acetylation 
or methylation (4). Cytosine methylation at CpG dinucleotides 
is typically considered a repressive modification associated with 
inactive chromatin. The 5mC modification is generated de novo 
by the DNA methyltransferases, DNMT3a and DNMT3b, while 
DNA methylation is maintained during replication by DNMT1 
using the already methylated DNA strand as a template. 5mC can 
be converted to 5-hmC by the ten–eleven translocation (TET) 
proteins, an α-ketoglutarate-dependent family of oxidases. 
5-hmC can not only serve as a stable mark allowing for activa-
tion of gene expression but also serve as an intermediate step to 
DNA demethylation through the base excision repair pathway 
(5). In addition to DNA modifications, posttranslational histone 
tail modifications can serve as a repressive or activating signal 
depending on the site on the histone tail being modified, number 
of groups added, and the region of chromatin where the modifi-
cation occurs (for example, promoter versus intergenic regions). 
Acetylation of histone tails is an important epigenetic regulation 
that adds negative charge to histones and is typically charac-
teristic of transcriptionally active, non-compact chromatin (6). 
The enzymes that add and remove the acetyl group from histone 
tails are termed histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), respectively. Unlike most histone tail 
acetylation, histone tail methylation can be activating or repress-
ing. As with other histone tail modifications, there are numerous 
enzymes involved in methylating or demethylating histone tails. 
Common DNA and histone tail modifications and the writer or 
eraser enzymes that add or remove them that are discussed in this 
review are listed in Table 1.
Together, these epigenetic modifications influence gene 
expression by altering chromatin structure (7). This can result 
in genes being silenced when in closed, highly compacted 
heterochromatin, or active in open euchromatin that is readily 
accessible to transcription factors. In addition to altering the 
compaction of the local chromatin landscape, epigenetic modi-
fications can serve as signals to recruit other regulatory factors 
including transcription factors to influence gene expression. 
Epigenetic modifiers have been documented to interact with 
transcription factors in several different ways. Indirectly, the 
marks deposited by epigenetic regulators can recruit or prevent 
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transcription factor binding. More directly, these epigenetic 
modifiers can be recruited to their target genes by transcription 
factors. The epigenetic enzymes then modify histone tails or 
DNA in this targeted region, or in some instances, they can be 
prevented from binding to chromatin by transcription factors. 
Moreover, epigenetic modifiers can posttranslationally modify 
the transcription factors themselves, which subsequently alters 
the activity and/or binding of these transcription factors to the 
DNA or to other chromatin modifying proteins. Various histone-
modifying enzymes and their marks have been implicated in the 
pathogenesis of cardiovascular disease (8–13), and the impor-
tance of their complex interactions with transcription factors is 
increasingly being investigated and better understood. Our focus 
in this review is to describe examples of these interactions that 
occur in settings of cardiovascular disease and highlight ques-
tions that remain to be investigated.
Although few studies have investigated the role of these 
interactions in cardiovascular disease, it is essential to elucidate 
how transcription factors and chromatin modifiers interact to 
understand cardiovascular disease pathology at a basic level. By 
understanding these interactions, we will be able to, ultimately, 
develop novel therapeutics to treat cardiovascular diseases. 
Although it has been established that several transcription 
factors implicated in cardiovascular disease pathogenesis are 
epigenetically regulated, this review will primarily focus on the 
interactions of transcription factors and DNA modifiers, histone 
methylation enzymes, and histone acetylation enzymes in the 
regulation of gene expression in various cell types and settings of 
cardiovascular disease.
HiSTONe aCeTYlaTiON iN 
CaRDiOvaSCUlaR DiSeaSe
Histone acetylation and Cardiovascular 
Development
Pathologic cardiac hypertrophy can occur in response to increased 
workload on the heart and is characterized by major changes in 
gene expression. There are distinct programs of gene expression 
observed in the fetal, neonatal, adult, and pathologically remod-
eling heart. Upregulation of fetal cardiac genes [e.g., ANF, brain 
natriuretic peptide (BNP)] is important in cardiac development, 
but their expression is generally reduced in adult cardiomyocytes. 
In the case of cardiomyocyte hypertrophy and hypervolemic 
states, their expression becomes reactivated (14, 15). Several 
transcription factors including GATA4 regulate cardiac genes in 
cardiac development and heart diseases like cardiac hypertrophy 
or congenital heart disease when dysregulated (14, 15). These 
transcription factors influence cardiac-specific gene expression 
not only through direct DNA binding but also through interac-
tions with HATs and HDACs. For example, hypertrophic stimuli 
induce the expression of cardiac genes in cardiomyocytes through 
recruitment of a p300-GATA4-Cdk9 complex (Figure 1A) (16). 
Cdk9 is also required for p300-induced acetylation of GATA4. 
Conversely, the scaffold protein receptor for activated protein 
kinase C1 (RACK1) inhibits the hypertrophic response by pre-
venting the interaction between GATA4 and p300 (Figure 1A) 
(17). These findings highlight the diverse role for p300 in being 
recruited to promoters to regulate gene expression as well as 
directly acetylating the transcription factor recruiting it. These 
two roles of HATs are likely not mutually exclusive and can be 
challenging to differentiate when identifying the role of HATs in 
regulation of gene expression.
Histone deacetylases also have similar complex roles in car-
diovascular development and disease (21). For example, HDAC2 
has opposing effects on genes involved in cardiomyocyte prolif-
eration and hypertrophy (22, 23). HDAC2 deacetylates GATA4 
to prevent its activation (22), but still promotes hypertrophic 
gene expression by associating with the transcription factor Ying 
Yang 1 (YY1) to promote activation of the fetal cardiac gene BNP 
in rat neonatal cardiomyocytes in vitro (23). However, it was not 
determined whether YY1 and HDAC2 co-localize at the BNP 
promoter or if knockdown of YY1 prevented HDAC2 binding to 
the promoter. These findings are in contrast to the activating role 
normally attributed to histone acetylation and the inactivating 
role for HDACs. However, while less common, gene activation 
by HDACs has been previously reported and could potentially be 
attributed to steric hindrance by the acetylated histone itself or 
another factor binding the acetylated region (24). The opposing 
roles for HDACs and histone acetylation are likely involved in 
numerous settings of cardiovascular disease.
Distinct HDAC complexes also play a more traditional role 
in repressing hypertrophic gene expression. In ventricular car-
diomyocytes, ANF expression is repressed by the transcription 
factor neuron-restrictive silencer factor (NRSF) when it is associ-
ated with a mSin3-HDAC1/2 complex. Together, this complex 
coordinates deacetylation of NRSF-binding elements upstream 
of ANF (Figure 1B) (19). Moreover, NRSF also associates with 
HDAC4/5 to repress ANF expression, and this interaction is 
decreased in models of cardiac hypertrophy (20). HDACs play 
an important role in cardiac development and disease (25–27) 
as global inhibition of HDACs using pharmacologic inhibi-
tors reduced hypertrophy in angiotensin II (AngII) and aortic 
banding mouse models of cardiac hypertrophy (28). However, 
whether these responses are dependent on their deacetylation of 
transcription factors, deacetylation of histones following recruit-
ment by transcription factors to promoters, or a combination of 
both requires further elucidation.
Histone acetylation and vascular Smooth 
Muscle Cells (vSMCs)
Unlike cardiac and skeletal myocytes, VSMCs do not terminally 
differentiate, but retain a plasticity to dedifferentiate in response 
to environmental cues. VSMC dedifferentiation to synthetic or 
inflammatory phenotypes contributes to cardiovascular patholo-
gies including intimal hyperplasia and atherosclerosis (29, 30). 
Growth factors and cytokines including transforming growth factor 
(TGF)-β, platelet-derived growth factor (PDGF), interferon-γ 
(IFNγ), and interleukin (IL)-1β can dramatically alter VSMC 
phenotype (29, 31). Epigenetics has also been shown to play an 
important role in regulation of VSMC phenotype [reviewed in 
Ref. (11, 12)]. In general, HAT activity promotes, while HDAC 
activity represses smooth muscle-specific gene expression (12), 
which is mediated through interactions between several key 
transcription factors.
FiGURe 1 | examples of chromatin-modifying enzymes and transcription factor complexes that interact to regulate cardiac gene expression.  
(a) p300 acetylates GATA4 and, through interaction with Cdk9, hyperacetylates cardiac gene promoters (16). Interaction of p300, GATA4, and Cdk9 can be 
prevented by RACK1 (17). Nkx2.5 also interacts with the histone demethylase UTX (18). (b) However, neuron-restrictive silencer factor (NRSF) in a complex with 
mSin3 and HDAC1/2 deacetylates cardiac gene promoters resulting in repression of cardiac gene expression (19). NRSF also interacts with HDAC4/5 to repress 
cardiac gene expression (20), but the contexts in which NRSF interacts with each histone deacetylase (HDAC) require further elucidation.
4
Bauer and Martin Epigenetic and Transcription Factor Interactions
Frontiers in Cardiovascular Medicine | www.frontiersin.org April 2017 | Volume 4 | Article 19
Myocardin, MRTFs, and SRF are master regulators of the 
muscle phenotype, with roles in lineage identity and muscle-
specific gene expression in cardiac, smooth, and skeletal muscle. 
While myocardin promotes cardiac and smooth muscle gene 
expression, it represses the skeletal muscle program (32). In all 
of these tissues, SRF binds to CArG elements in muscle-specific 
genes, with cofactors determining the expression of cytoskeletal 
and muscle-specific genes. HATs and HDACs interact with these 
essential transcriptional regulators. Complexes of SRF and CBP 
enable activation of smooth muscle contractile marker promot-
ers like SM22α through hyperacetylation of their promoters in 
VSMCs (Figure  2A) (33). Enhanced activation of the SMC-
specific promoters was found to be not only due to increased 
H3Ac (34), but also due to p300-dependent acetylation of 
myocardin (Figure 2A) (35). Acetylation of myocardin enhances 
its association with SRF and CArG boxes and is required for acti-
vation of SMC genes. Moreover, myocardin acetylation leads to 
its dissociation from HDAC5 (35). HDAC5 along with HDAC2 
and HDAC4 deacetylate SMC marker genes downstream of 
PDGF-BB treatment. This inhibits binding of MRTFs and myo-
cardin and reduces contractile gene expression (34, 36). This 
family of transcription factors and coactivators plays a clear role 
in mediating recruitment of epigenetic factors including HATs, 
HDACs, and histone methylating and demethylating enzymes 
(described in Section “Histone Methylation and Myocardin, 
MRTFs, and SRF Interactions”). The acetylation of myocardin 
itself provides another example of a transcriptional regulator 
that both recruits and is modified by HATs/HDACs. Given 
their importance in SMC phenotype, it would be of interest to 
determine whether the SRF cofactors, myocardin and MRTFs, 
similarly interact with additional epigenetic regulators.
The Kruppel-like factor (KLF) family of transcription factors 
play important roles in VSMC phenotypic modulation, and 
several studies have demonstrated a role for interactions between 
KLFs, p300, and HDACs in the regulation of VSMC plasticity. 
Specifically, KLF5, retinoic acid receptor (RAR)-α, and HDAC2 
interact at the p21 promoter to repress its expression and induce 
proliferation in VSMCs (40). When stimulated with a RAR-α 
agonist, HDAC2 deacetylates KLF5 to dissociate it from the p21 
promoter. This dissociation allowed p300 to acetylate RAR-α to 
stabilize its binding, activate the p21 promoter, and block VSMC 
proliferation. Similarly, KLF4 can also activate gene transcription 
through its interaction with HATs. KLF4 associates with p300 
following TGF-β1 stimulation in VSMC leading to increased H3 
acetylation at TGF-β control elements of the p21 promoter (41). 
TGF-β also promotes p300 interaction with Smad3 to induce 
FiGURe 2 | Regulation of SMC contractile marker genes by epigenetic modifiers and transcription factors. (a) p300 acetylates H3 and myocardin  
in SMCs promoting myocardin dissociation from HDAC5 and interaction with SRF (34, 35). CBP and SRF also interact to hyperacetylate SMC contractile marker 
promoters (33). Together myocardin and SRF bind to CArG boxes in SMC contractile marker promoters to induce their expression. (b) In contrast, dedifferentiation 
stimuli like platelet-derived growth factor (PDGF) promote KLF4-dependent recruitment of histone deacetylases (HDACs) 2, 4, and 5 and subsequent deacetylation 
of SMC marker gene promoters. (37–39). This deacetylation prevents SRF and MRTF binding to contractile genes and their activation.
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acetylation of the SM22a promoter (42). Vascular injury, growth 
factors, and oxidized phospholipids can also induce KLF4 and 
pELK1 binding to contractile gene promoters leading to recruit-
ment of HDAC2 and HDAC5, deacetylation of histones in these 
regions, inhibition of SRF binding, and repression of contractile 
gene expression (Figure  2B) (37–39). KLF4’s complex role in 
regulating VSMC phenotypic switching (43) appears to be medi-
ated through both modifications by HATs and HDACs as well 
as recruitment of them to target promoters and subsequent 
modifi cation of histone acetylation. Perhaps interaction of KLF4 
with these epigenetic regulators could account for its context-
dependent effects and may provide a useful system in which to 
study recruitment of epigenetic regulators to specific loci in one 
context, but not another.
Histone acetylation and eCs
Histone deacetylases and HATs also have a known role in differen-
tiation and maintenance of EC homeostasis, including effects on 
proliferation, migration, and apoptosis (44). EC maintenance and 
angiogenesis ensure adequate blood supply to tissues, while EC 
inflammation is a major driver of atherosclerosis and subsequent 
ischemia or infarct. Vascular endothelial-cadherin (VE-cadherin) 
is a key component of adherens junctions and flow mechano-
sensing in ECs and is required for vascular integrity (45). While 
MRTFs and SRF have been described in terms of their roles in 
muscle-specific gene expression, these factors are also expressed 
ubiquitously in somatic cells, including ECs, where they are essen-
tial regulators of cytoskeletal genes. MRTF-A interacts with p300 
in ECs to induce VE-cadherin expression (46). Overexpression 
of p300 enhanced vascular endothelial growth factor (VEGF)-
dependent increased expression of VE-cadherin through upregu-
lation of H3Ac and H4Ac and subsequent induction of MRTF-A 
recruitment to the VE-cadherin promoter in human umbilical 
vein endothelial cells (HUVECs) (46).
β-Catenin is another cadherin that interacts with VE-cadherin 
and promotes cell–cell adhesions intracellularly as a part of its 
structural role (47). It is also an important signaling molecule 
that induces gene transcription downstream of Wnt signaling 
(48) and is involved in angiogenesis (49). In ECs, prolifera-
tion is suppressed through downregulation of cyclin D1 when 
β-catenin is sequestered in the cytoplasm by direct interaction 
with HDAC7 (50). Upon VEGF treatment, HDAC7 is degraded 
and β-catenin translocates to the nucleus. Once in the nucleus, 
activated β-catenin upregulates proangiogenic factors like VEGF 
6Bauer and Martin Epigenetic and Transcription Factor Interactions
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or IL-8 (51). Conversely, expression of IL-8 can be repressed by 
the transcription factor Bach1. Modulation of Bach1 expression 
alters H3 and H4 acetylation at the IL-8 promoter, and Bach1 
prevents interaction between β-catenin and p300/CBP (52). 
Indeed, it has previously been reported that p300-dependent 
histone acetylation can recruit β-catenin to enhancers during 
stem cell differentiation (53) and, conversely, that β-catenin 
can recruit p300/CBP to target genes in colon cancer cells and 
Xenopus embryos (54, 55). These findings suggest that interaction 
of p300/CBP and β-catenin is a common mechanism to regulate 
gene expression, and future studies should investigate the role of 
this interaction in regulation of other genes in ECs and in other 
settings of vascular disease.
In addition to regulation of proangiogenic factors, HATs have 
a role in regulating numerous transcription factors involved in 
EC function. p300, H3Ac, and p65 were found to be simultane-
ously localized to NF-kB binding sites at the FasL promoter, a 
proapoptotic factor, in ECs following antiangiogenic treatment 
(56). Conversely, NF-kB interacted with HDAC1, while p300, 
H3Ac, and H4Ac decreased at the cFLIP promoter, an antiapop-
totic factor. This leads to repression of its expression indicating 
that NF-kB interaction with both HDACs and HATs is important 
in regulating EC function through changes in histone acetylation 
at numerous EC genes. Indeed, VCAM-1 expression is also acti-
vated when p300 and NF-kB p65 directly bind to the VCAM-1 
promoter in ECs and acetylate H3K9 and H4K8 (57). In addition 
to interacting with NF-kB at gene promoters, p300 also acetylates 
p65 itself to promote its activation (57). This also leads to induc-
tion of VCAM-1 expression, an important adhesion molecule. 
Acetylation of p65 by p300 is prevented through phosphorylation 
of p300 by AMPK overexpression. AMPK becomes activated in 
response to numerous stresses including nutrient deprivation 
and inflammation, and it has been reported to have a vasculo-
protective role in the endothelium (58). It is likely that p300 (and 
potentially CBP) has the dual role of histone acetylation through 
recruitment by a transcription factor in addition to acetylation of 
that transcription factor itself in regulation of gene expression in 
settings in addition to those presented throughout this review.
p300 regulation of NF-kB is also involved in activation of the 
endothelial nitric oxides synthase (eNOS) promoter, the major 
source of NO in response to acute laminar shear stress, which 
is an important protective process in normal EC function and 
signaling (59). EC response to flow is highly dependent on the 
amount, duration, and direction of flow (60, 61). High laminar 
shear stress transiently upregulates NF-kB and pro-inflammatory 
pathways, increases eNOS expression, aligns ECs in the direc-
tion of flow, and promotes an atheroprotective EC phenotype 
(62). Conversely, disturbed flow leads to sustained expression 
of pro-inflammatory pathways, a failure of EC alignment, and a 
proatherogenic phenotype. It is reported that NF-kB activates the 
eNOS promoter with laminar shear stress (63), which is mediated 
by p300 through acetylation of NF-kB and also increased H3Ac 
and H4Ac at the eNOS promoter following shear in HUVECs 
leading to increased eNOS expression (59). Although this study 
did not evaluate whether p300 and NF-kB directly interact at 
shear response elements in the eNOS promoter, it is likely that 
these factors may also interact at these elements to regulate eNOS 
expression. Together, these studies suggest that p300 cooperates 
with NF-kB to regulate eNOS expression implicating a role for 
chromatin modifiers in regulating the shear response through 
coordination of transcription factors. However, the in vivo role 
of such an interaction in ECs exposed to fluid shear stress in 
atherogenesis remains to be investigated.
In addition to disturbed flow, reactive oxygen species (ROS) 
also contribute to the pathogenesis of cardiovascular diseases 
(64). A significant source of ROS in the vasculature is the family 
of NADPH oxidases or Nox enzymes (65). These are oxidoreduc-
tases that have slightly different mechanisms of activation and 
roles. One Nox family member, Nox4, is the predominant isoform 
expressed in ECs. In HUVECs, expression of Nox4 is repressed 
through inhibition of HDACs with scriptaid (66). This leads to 
increased H4Ac and H3K27Ac, which prevents c-jun and RNA 
polymerase (RNAP II) from binding to the endogenous Nox4 
promoter, thus decreasing Nox4 expression (66). These findings 
provide an example of how histone modifications are able to pre-
vent binding of transcriptional machinery to promoter elements. 
Moreover, they provide further support to a less typical activating 
role for HDACs in regulating gene expression.
Indeed, the class II HDAC SirT1 also positively regulates 
antioxidant genes such as catalase and manganese superoxide 
dismutase in ECs in vitro (67). SirT1 deacetylates H4K16 when 
recruited to promoters of these antioxidant genes leading to 
increased promoter clearance by RNAP II despite its decreased 
binding to the proximal promoter. As with other HDACs, in addi-
tion to modifying histones when recruited to gene promoters, 
SirT1 also directly modified the transcription factors involved in 
regulating antioxidant genes, FoxO3a and PGC1α, to promote 
stabilization of a PGC1α–FoxO3a complex (67). Whether the 
ternary complex of SirT1-FoxO3a-PGC1α may then be recruited 
to antioxidant genes to upregulate their expression in response 
to oxidative stress remains to be investigated. SirT1-dependent 
association with and deacetylation of the FoxO family of tran-
scription factors is also involved in regulation of angiogenesis 
(68). Together these studies demonstrate that modification of 
transcription factors while also being recruited by them to 
regulatory regions to modify chromatin structure is a common 
occurrence in regulation of gene expression. This is likely shared 
by many HATs and HDACs other than p300/CBP, HDACs, and 
SiRTs mentioned in this review and should be considered when 
investigating their role in cardiovascular disease. Moreover, the 
studies mentioned here discuss only some of the more commonly 
studied HATs and HDACs, but it is also likely that interaction 
of factors like GNAT or CLOCK with transcription factors is an 
essential component in gene regulation underlying cardiovascu-
lar pathogenesis.
HiSTONe MeTHYlaTiON iN 
CaRDiOvaSCUlaR DiSeaSe
Histone Methylation and Myocardin, 
MRTFs, and SRF interactions
In addition to cooperating with HATs and HDACs, the master 
regulators of muscle phenotype SRF, myocardin, and MRTFs 
FiGURe 3 | Regulation of endothelin 1 by COMPaSS components and MRTF-a in endothelial cell. Angiotensin II (AngII) treatment induces the interaction  
of COMPASS components WDR5 and ASH2 with MRFT-A at the endothelin 1 promoter leading to upregulation of ET-1 expression (72).
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also interact with histone methyltransferases and demethylases 
to regulate gene expression. SRF and other core cardiac tran-
scription factors such as Tbx5 and Nkx2.5 interact with UTX, a 
H3K27-specific histone demethylase, to promote an open chro-
matin conformation and enhancer activation of target cardiac 
genes like ANF (Figure 1A) (18). Prevention of recruitment of 
UTX to enhancers of cardiac-specific genes using UTX null mice 
impaired cardiac differentiation, demonstrating the importance 
of this demethylase in regulating cardiac development. However, 
whether the loss of the specific interaction of UTX and Tbx5 or 
Nkx2.5 is primarily driving the impaired cardiac differentiation 
in  vivo is unknown. Interaction of histone methylation and 
transcription factors in regulating development is not unique 
to cardiomyocytes. Indeed, the SMC-specific program of gene 
expression is activated by recruitment of WDR5, a necessary 
component of the SET/MLL family of methyltransferases, by 
SMC-selective pituitary homeobox 2 (69). WDR5 promotes 
expression of the SMC-specific gene program through mediating 
H3K4 methylation of SMC marker promoters. Together, these 
studies demonstrate a role for core and/or cell type-specific 
transcription factors in recruiting ubiquitously expressed histone 
methyltransferases and demethylases in control of lineage-
specific gene expression.
SRF, myocardin, and MRTFs also mediate changes in gene 
expression in response to environmental stimuli through inter-
actions with histone methyltransferases and demethylases. The 
histone demethylase JMJD2a cooperates with SRF/myocardin 
to upregulate expression of four-and-a-half LIM domains 1 
(FHL1) (70), an important biomechanical stress sensor involved 
in cardiac hypertrophy (71). JMJD2a binds to the Fhl1 promoter 
and downregulates H3K9 methylation in response to transverse 
aortic constriction (TAC) (70). JMJD2a and its activity likely 
enhance binding of SRF/myocardin to the Fhl1 promoter, 
and SRF was required for JMJD2a-dependent activation of 
an Fhl1 promoter reporter. JMJD2a knockdown attenuated 
hypertrophy following TAC (70). The authors hypothesize that 
JMJD2a interaction with SRF/myocardin may be a feed-forward 
loop in which SRF/myocardin initially recruits JMJD2a to the 
Fhl1 promoter leading to downregulation of H3K9me3 and 
subsequent stabilization of SRF/myocardin binding. This study 
demonstrates the complexity in understanding whether chro-
matin modifiers or transcription factors recruit the other to gene 
regulatory sites and highlights the need for detailed mechanistic 
studies to understand these interactions in the regulation of 
gene expression.
In addition to interaction with demethylases, MRTFs also 
cooperate with methyltransferases to regulate gene expression. 
For example, in ECs, MRTF-A mediates the recruitment and 
interaction of the COMPASS components ASH2 and WDR5 
and chromatin remodelers to the ET-1 promoter following 
AngII stimulation (Figure 3) (72). Recruitment of this complex 
promotes transcription of ET-1, which plays an important role 
in vasoconstriction, endothelial dysfunction, and development 
in numerous cardiovascular diseases (73). MRTF-A interac-
tion with COMPASS and its components such as ASH2 is also 
important in regulation of inflammatory stimuli downstream 
of ET-1 (74), and LPS promoted the same MRTF-A-dependent 
recruitment of these COMPASS components to NF-kB target 
promoters in macrophages as demonstrated by ChIP and reChIP 
assays (75). Furthermore, knockdown of MRTF-A reduced the 
binding of COMPASS proteins demonstrating that, in this study, 
the transcription factor recruited the chromatin modifying 
proteins, but whether that is the case in all settings remains to be 
determined. Together, these findings demonstrate that the SRF, 
myocardin, and MRTF family of transcription factors mediate 
the recruitment or are potentially recruited by both demethyl-
ases and methyltransferases in numerous cellular contexts sug-
gesting widespread applicability of the role of these interactions 
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in cardiovascular pathologies. Furthermore, as SRF/myocardin 
are ubiquitously expressed proteins involved in the regulation of 
cytoskeletal genes, there are likely cell type-specific and locus-
specific interactions between them and epigenetic regulators.
Histone Methylation and vascular 
Homeostasis
Endothelial homeostasis is also regulated by cooperation of 
transcription factors and histone methyltransferases and dem-
ethylases. KLF2 is an important EC transcription factor that 
promotes an anti-inflammatory and antithrombotic surface 
through regulation of numerous genes including eNOS and 
thrombomodulin (76). Laminar flow activates MEF2, which 
promotes transcription of KLF2. The proatherogenic stimulus 
low-density lipoprotein (LDL) alters binding interactions at 
the KLF2 promoter, decreasing MEF2 binding while increasing 
occupation by the epigenetic reader, MECP2, and H3K27 histone 
methyltransferase, EZH2, leading to repressed KLF2 expression 
(77). As the binding sites for these factors were overlapping 
or all within a 169 base pair promoter region, these findings 
suggest that these epigenetic factors can competitively bind to 
promoters to inhibit transcription factor binding and subsequent 
gene activation.
Endothelial cells are sensitive to hypoxia, a key stimulus for 
angiogenesis. Transcription factor-facilitated chromatin interac-
tions with epigenetic modifiers are also observed with hypoxia-
dependent upregulation of the glucose transporter, GLUT3, in 
HUVECs. Expression of this gene was increased through HIF1-
α-dependent recruitment of the demethylase KDM3A and subse-
quent demethylation of H3K9 at the transcriptional start site and 
enhancer regions of GLUT3 (SLC2A3) (78). HIF1-α and KDM3a 
coimmunoprecipitated, and knockdown of HIF1-α prevented 
binding of KDM3A to regulatory sites upstream of GLUT3. 
Therefore, HIF1-α and KDM3a cooperate to increase GLUT3 
expression and subsequent glucose uptake, which is important to 
maintain energy availability under hypoxic conditions.
In addition to histone lysine methylation, histone arginine 
methylation also influences transcription factor recruitment 
during SMC phenotypic switching in atherogenic conditions 
(79). Smooth muscle-specific knockout of the Wnt co-receptor, 
LDL receptor-related protein (LRP6), in LDL knockout mice fed 
a high-fat diet, resulted in increases in osteochondrogenic genes 
like osteopontin (OPN) and vascular calcification. Increased 
OPN expression was mediated by protein arginine methyltrans-
ferase 4 (PRMT4)-dependent dimethylation of Arg-17 on histone 
H3. This H3R17me2 mark recruits the transcription factor USF1, 
leading to activation of the OPN promoter. Recruitment of USF1 
and induction of OPN expression were inhibited by the arginine 
demethylase JMJD6 (79). Although this study elucidated a role for 
PRMT4 and USF1 cooperation in upregulating OPN expression 
in the absence of LRP-mediated Wnt signaling, it is possible that 
these factors also control OPN upregulation in other instances of 
vascular calcification. Together, these findings demonstrate that 
histone methylating and demethylating enzymes cooperate with 
a variety of transcription factors in numerous cellular contexts to 
regulate gene expression.
DNa MeTHYlaTiON iN 
CaRDiOvaSCUlaR DiSeaSe
DNa Modifications and Transcription 
Factor interactions
Aberrant expression of DNMTs, TETs, or their subsequent DNA 
modifications is involved in various cardiovascular diseases 
(11, 80). However, the potential role of interactions between these 
enzymes or their marks and transcription factors in the molecu-
lar pathogenesis of these diseases are less well understood. DNA 
methylation appears to have a pro-inflammatory role (81) and is 
important in regulation of endothelial cell-specific expression of 
eNOS (82). DNA methylation of the eNOS promoter in non-EC 
types prevents binding of the transcription factors Sp1, Sp3, and 
Ets1, whereas hypomethylation of this promoter in ECs allows 
for these factors to drive its expression (83). Interestingly, eNOS 
expression is also regulated through aberrant DNA methylation 
of the promoters of transcription factors like KLF2 and KLF4 
that bind and activate the eNOS promoter (77, 84). Disturbed 
flow, associated with atheroprone regions of the vasculature (85), 
increased the methylation of the KLF4 promoter by DNMT3a. 
This methylation precludes binding of the transcription factor 
MEF2, a key driver of KLF4 expression. The resulting decrease 
in KLF4 expression subsequently reduces eNOS expression in 
ECs (84).
DNa Methylation Modifiers and 
Transcription Factor interactions
While these eNOS regulation studies suggest a role for DNA 
methylation in preventing transcription factor binding to pro-
moters, to our knowledge, direct interaction of DNA methylating 
and demethylating enzymes with transcription factors to regulate 
gene expression in the context of cardiovascular diseases has not 
been investigated. However, there is evidence that transcription 
factors can guide DNMTs and TETs to particular promoter regions 
in other cell types including bone marrow-derived dendritic cells, 
neurons, and adipocytes (86–89). For example, during inflam-
mation resolution, TET2 is recruited to Il-6 promoter by IκBζ 
in bone marrow-derived dendritic cells to repress IL-6 expres-
sion independent of TET2 enzymatic activity (86). IL-6 is also 
proatherogenic by promoting inflammatory cell infiltration into 
the plaque, endothelial dysfunction, and VSMC proliferation, 
and uptake of LDL (90). TET2 has recently been implicated as a 
master epigenetic regulator of SMC phenotype, and its expression 
is inversely correlated with severity of atherosclerosis in human 
plaques (91). A recent study revealed an opposing relationship 
between TET2 and DNMT1 in SMCs, with DNMT1 leading 
to methylation of the TET2 promoter, suppressing expression 
of TET2 and myocardin. Furthermore, DNMT inhibitors sup-
pressed both atherosclerosis and intimal hyperplasia (92). While 
these factors regulate expression of KLF4 and myocardin (91, 92), 
whether and how TET2 and DNMTs interact with SMC-specific 
transcription factors is not yet known but will be important to 
determine. These studies demonstrate that DNA-modifying 
enzymes associate with transcription factors in numerous cell 
contexts, suggesting that perhaps similar associations occur to 
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regulate gene expression in the pathogenesis of cardiovascular 
disease.
OTHeR HiSTONe MODiFieRS aND 
CaRDiOvaSCUlaR DiSeaSe
DNA methylation, histone methylation, and histone acetylation 
along with the enzymes that make these marks are the most 
commonly studied epigenetic regulators. However, there are also 
several other types of modifications and enzymes that have yet 
to be studied. Histone phosphorylation is commonly used as 
a marker of cell division although it also plays a role in DNA 
repair, chromatin compaction during cell division, apoptosis, and 
even regulation of transcription (93). As with phosphorylation of 
other proteins, there are numerous enzymes that phosphorylate 
and dephosphorylate histones, but few have been studied for their 
potential role in cardiovascular disease pathogenesis. Similar to 
histone phosphorylation, histone ubiquitination is regulated by 
numerous ubiquitin ligases and deubiquitinating enzymes and 
is also involved in many processes including DNA repair and 
transcriptional regulation (94, 95). Although it is known that dys-
regulated ubiquitination of proteins is involved in cardiovascular 
disease development and progression (96, 97), the potential roles 
of histone ubiquitination or the enzymes that add or remove this 
mark are unclear. It has been shown that ubiquitin-proteasome-
mediated degradation of histone variants is upregulated during 
cardiac hypertrophy (98). Moreover, in congenital heart disease, 
there are de novo mutations in genes involved in ubiquitination 
of histones (99), suggesting that histone ubiquitination might 
be important in cardiovascular disease pathology. Another 
histone modification less commonly studied is O-linked 
β-N-acetylglucosamine (O-GlcNAc). A role for O-GlcNAcylated 
non-histone proteins, along with the enzymes that catalyze the 
addition and removal of it, is well established in cardiovascular 
pathologies (100). However, few substrates that mediate these 
pathologies have been identified, and the role of O-GlcNAc-
modified histones in cardiovascular disease is unknown. Studies 
on these enzymes and others, including chromatin remodeling 
enzymes, are necessary to better understand cardiovascular 
disease pathogenesis at a mechanistic level.
SUMMaRY aND PeRSPeCTiveS
Cardiovascular diseases continue to be a major health concern 
in the United States and worldwide. Although considerable pro-
gress has been made in understanding the cellular and molecular 
mechanisms underlying cardiovascular disease pathology, 
few studies have investigated how transcription factors and 
chromatin modifiers including DNA methylation modifiers, 
histone methylation enzymes, and histone acetylation modifiers 
cooperate to regulate gene expression underlying cardiovascular 
disease. While this area of investigation is still relatively under-
developed due to challenges in methodology described below, it 
is becoming clear that control of gene expression is a coordinated 
effort between transcription factors and chromatin remodeling 
enzymes. There are several classical modes in which these factors 
can influence each other’s activity. These include the following: 
(1) DNA or histone modifications prevent or induce transcrip-
tion factor binding (e.g., H4Ac and H3K27Ac preventing c-jun 
and RNAP II binding in Section “Histone Acetylation and ECs”). 
(2) HATs or HDACs posttranslationally modify transcription fac-
tors to alter their binding or specificity (e.g., p300 and HDAC2 
modification of GATA4 in Section “Histone Acetylation and 
Cardiovascular Development”). (3) Chromatin modifiers are 
recruited to (or excluded from) specific loci by transcription fac-
tors (e.g., MRTF-A recruitment of COMPASS in Section “Histone 
Methylation and Myocardin, MRTFs, and SRF Interactions”). 
(4) Transcription factors are recruited to (or excluded from) spe-
cific loci by the presence of a chromatin modifying enzyme (e.g., 
JMJD2a and SRF/myocardin in Section “Histone Methylation 
and Myocardin, MRTFs, and SRF Interactions”). In this review, 
we have summarized examples of these paradigms that have been 
implicated in specific gene regulation in systems relevant to car-
diovascular disease. Many of the studies, however, have reported 
an interaction between a transcription factor and epigenetic 
modifier without demonstrating that the specific interaction (or 
lack thereof) is necessary for cardiovascular disease progression. 
This level of evidence can be difficult to achieve with current 
methods (see below). However, the importance of these interac-
tions in cardiovascular disease is being realized and will likely be 
further developed in the future as methods improve.
Although further studies are necessary to better understand 
the intersection between transcriptional and epigenetic regula-
tion of gene expression in cardiovascular disease, conducting 
these studies proves to be challenging for three main reasons. 
First, several of these chromatin modifying proteins, particu-
larly HATs and HDACs, have roles in modifying non-histone 
proteins like transcription factors. Therefore, it remains difficult 
to elucidate whether effects on gene expression are due to direct 
interaction of these proteins to modify the transcription factor 
itself or interaction for recruitment and modulation of chromatin 
structure. Second, chromatin-modifying proteins often work in 
larger complexes or recruit other epigenetic factors that compli-
cate determining how factors interact to regulate gene expression. 
Finally, many of the techniques currently used in these studies 
do not always sufficiently address whether one factor recruits 
another or how they interact to modify control gene activation 
or repression. Techniques to detect colocalization of transcription 
factors and epigenetic modifiers at gene loci [e.g., ChIP-reChIP 
(101, 102)], to overcome cellular heterogeneity by investigat-
ing chromatin changes at the single-cell level [e.g., single-cell 
ChIP-Seq (103)], or to detect what is bound at a specific locus 
in an unbiased manner [e.g., reverse ChIP (104)] have been 
developed. However, these methods have technical limitations 
including amount of sample required, low yields, and high costs. 
There is a need to continue to improve upon these methods to 
allow their more widespread use in the field. Therefore, many 
studies, including many described in this review, perform a 
single ChIP to demonstrate binding of factors individually to 
similar regions followed by separate coimmunoprecipitation 
experiments documenting the interaction of these factors (which 
may or may not occur at the same location in chromatin). Ideally, 
studies would demonstrate that specific disruption of interaction 
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between these factors prevents downstream gene transcription 
and the functional readout or they would perform sequential 
chromatin immunoprecipitation experiments (ChIP-reChIP) to 
show that these transcription factors and chromatin modifiers are 
colocalized upstream of a particular gene. Although, incorporat-
ing knockdown of either factor could demonstrate that binding 
of one determines binding of the other, use of knockdown or 
overexpression techniques leads to difficulty in determining 
if observed outcomes are due to direct or indirect effects of 
the factors interacting. While assessing interactions between 
endogenous factors in vivo would be ideal, transcription factors 
and chromatin modifiers are oftentimes expressed at low levels 
or there is a lack of reliable reagents. As such, epigenetic studies 
commonly employ in vitro methods including use of exogenous 
promoters or overexpression of factors. However, as culturing 
cells in vitro alone has been shown to alter the epigenome (105), 
studies primarily employed in vitro have several limitations and 
may not be an accurate representation of what occurs in the set-
ting of cardiovascular disease. Therefore, a combination of studies 
using in vivo methods, primary cells, and endogenous promoters 
and expression of factors will be important in elucidating the 
relevance of these interactions in cardiovascular disease.
With the realization of the complexity, but necessity, of 
studying the interaction of transcription factors and epigenetic 
modifiers in regulation of gene expression, and continued 
improvements in necessary techniques, several important ques-
tions should be addressed. As previously described, the roles of 
other chromatin-modifying proteins and identification of new 
transcription factor–epigenetic regulator interactions in patho-
genesis of cardiovascular disease remain an important area of 
investigation. In addition, many studies focus on the interaction 
of the proteins at promoter regions to regulate gene expres-
sion, but such interactions at enhancer elements, repressors, or 
elsewhere remain largely unexplored. Perhaps most importantly, 
the mechanisms that govern the locus specificity of these interac-
tions is of significant interest given that many of the epigenetic 
modifiers and transcription factors are ubiquitously expressed. 
Perhaps, in some cases, binding motif sequence specificity of 
transcription factors can account for the locus-specific targeting 
of some epigenetic regulators if these factors interact to regulate 
gene expression. Conversely, DNA or histone modifications 
within a specific sequence may recruit transcription factors to 
a locus to regulate gene expression. However, these instances 
do not account for all situations and do not always address why 
these specific interactions occur at a single locus following a given 
stimulus. It is likely that signaling cascades generated by extra-
cellular stimuli converge on these transcriptional and epigenetic 
regulators in a context-specific manner, combined with a cohort 
of tissue-restricted proteins to ultimately determine tissue- and 
disease-specific gene regulation. Finally, this area of investigation 
is important as genome-wide association studies (GWAS) have 
identified many SNPs associated with cardiovascular disease. As 
most variants identified by GWAS lie outside of protein-coding 
regions (106), it is likely that many of these SNPs may reside in as 
yet-unidentified regulatory elements where transcription factors 
and chromatin modifiers interact. Addressing these questions will 
provide a better understanding of the mechanisms underlying 
cardiovascular disease pathogenesis that will allow the develop-
ment of better diagnostic tools and therapeutics to address this 
global health burden.
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